Diagnosis and Risk Stratification of non-alcoholic Steatohepatitis (NASH) - a Recommendation from Austrian Hepatologists

被引：0

作者：

Munda, Petra ^{[1
]}

Aigner, Elmar ^{[2
]}

Ferlitsch, Arnulf ^{[3
]}

Gschwantler, Michael ^{[4
]}

Hofer, Harald ^{[5
]}

Maieron, Andreas ^{[6
]}

Peck-Radosavljevic, Markus ^{[7
]}

Stadlbauer-Koellner, Vanessa ^{[8
]}

Wagner, Martin ^{[8
]}

机构：

[1] Med Univ Wien, AKH Wien, Vienna, Austria

[2] Paracelsus Med Privatuniv, Uniklinikum Salzburg, PMU, Salzburg, Austria

[3] KH Barmherzige Bruder Wien, Vienna, Austria

[4] KA Wilhelminenspital, Vienna, Austria

[5] Klinikum Wels Grieskirchen, Wels, Austria

[6] Univ Klinikum St Polten, St Polten, Austria

[7] Klinikum Klagenfurt Worthersee, Klagenfurt, Austria

[8] Med Univ Graz, Graz, Austria

来源：

WIENER KLINISCHE WOCHENSCHRIFT | 2020年 / 132卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P09

引用

页码：78 / 78

页数：1

共 50 条

[41] Management of patients with non-alcoholic steatohepatitis (NASH) in real life
Serfaty, Lawrence
LIVER INTERNATIONAL, 2018, 38 : 52 - 55
[42] Molecular mechanisms of fibrosis progression in non-alcoholic steatohepatitis (NASH)
Hellerbrand, C.
LIVER CIRRHOSIS: FROM PATHOPHYSIOLOGY TO DISEASE MANAGEMENT, 2008, 162 : 75 - +
[43] Insulin resistance is an independent defect in non-alcoholic steatohepatitis (NASH).
Vanni, E
Bugianesi, E
Gastaldelli, A
Gambino, R
Cassader, M
Ponti, V
Ferranninni, E
Pagano, G
Rizzetto, M
HEPATOLOGY, 2001, 34 (04) : 361A - 361A
[44] Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)
Lee, Jin Ha
Oh, Ji Young
Kim, Soo Hyun
Oh, In Jeong
Lee, Yong-ho
Lee, Keun Woo
Lee, Woong Hee
Kim, Jeong-Hwan
BIOMOLECULES, 2020, 10 (10) : 1 - 16
[45] RISK OF INCIDENT EXTRAHEPATIC CANCERS AMONG MEDICARE PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Fishman, Jesse
Kim, Yestle
Medicis, Joe
Davis, Matthew
Nunag, Dominic
Gish, Robert
HEPATOLOGY, 2024, 80 : S798 - S799
[46] Insulin resistance and clinical aspects of non-alcoholic steatohepatitis (NASH)
Agarwal, N
Sharma, BC
HEPATOLOGY RESEARCH, 2005, 33 (02) : 92 - 96
[47] A new approach to drug therapy in non-alcoholic steatohepatitis (NASH)
Fehér, J
Lengyel, G
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2003, 31 (06) : 537 - 551
[48] Role of pioglitazone (PIO) in patients with non-alcoholic steatohepatitis (NASH)
Belfort, RS
Harrison, S
Brown, K
Darland, C
Finch, J
Tio, F
Gastaldelli, A
Hardies, J
Berria, R
Dwivedi, S
Havranek, R
Balas, B
Fincke, C
DeFronzo, R
Cusi, K
DIABETOLOGIA, 2005, 48 : A280 - A280
[49] Mitochondrial oxidant stress in experimental non-alcoholic steatohepatitis (NASH)
不详
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2005, 41 (04): : 523 - 524
[50] MRI presentation of hepatocellular carcinoma in non-alcoholic steatohepatitis (NASH)
Al-Sharhan, Fatima
Dohan, Anthony
Barat, Maxime
Feddal, Adlane
Terris, Benoit
Pol, Stanislas
Mallet, Vincent
Soyer, Philippe
EUROPEAN JOURNAL OF RADIOLOGY, 2019, 119

← 1 2 3 4 5 →